<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650584</url>
  </required_header>
  <id_info>
    <org_study_id>S00231</org_study_id>
    <nct_id>NCT01650584</nct_id>
  </id_info>
  <brief_title>Evaluation of Ocular Comfort With ISTA Tears vs Systane</brief_title>
  <official_title>Evaluation of Ocular Comfort With ISTA Tears vs Systane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease&#xD;
      (DED)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Preference for One of the Treatments</measure>
    <time_frame>30 days</time_frame>
    <description>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total). Participants were asked to indicate which treatment they preferred, or if they preferred neither.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>ISTA Tears</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sterile ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISTA Tears</intervention_name>
    <description>sterile ophthalmic solution</description>
    <arm_group_label>ISTA Tears</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane</intervention_name>
    <description>Sterile ophthalmic solution</description>
    <arm_group_label>Systane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  OSDI &gt;12&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any active ocular disease other than dry eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim McNamara, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISTA Pharmaceuticals, Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <disposition_first_submitted>October 28, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 28, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 6, 2019</disposition_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall</title>
          <description>Each participant has 2 eyes. There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35">Each participant received one of 2 treatments in each eye.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total). The protocol required that participants be least 18 years of age, male or female. Participant demographic information was not collected.</population>
      <group_list>
        <group group_id="B1">
          <title>ISTA Tears</title>
          <description>Sterile ophthalmic solution&#xD;
ISTA Tears: sterile ophthalmic solution used in the right eye</description>
        </group>
        <group group_id="B2">
          <title>Systane</title>
          <description>Sterile ophthalmic solution&#xD;
Systane: Sterile ophthalmic solution used in the left eye</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Preference for One of the Treatments</title>
        <description>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total). Participants were asked to indicate which treatment they preferred, or if they preferred neither.</description>
        <time_frame>30 days</time_frame>
        <population>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total).</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Preference for One of the Treatments</title>
          <description>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total). Participants were asked to indicate which treatment they preferred, or if they preferred neither.</description>
          <population>There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISTA Tears preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systane preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISTA Tears</title>
          <description>Sterile ophthalmic solution&#xD;
ISTA Tears: sterile ophthalmic solution used in the right eye</description>
        </group>
        <group group_id="E2">
          <title>Systane</title>
          <description>Sterile ophthalmic solution&#xD;
Systane: Sterile ophthalmic solution used in the left eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for detail.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

